Shift Work Disorder Hits Hard (Image Credits: Unsplash)
Millions of workers across industries face the grind of early-morning shifts, often battling intense drowsiness that hampers performance and heightens risks. A groundbreaking clinical trial revealed that solriamfetol, a wake-promoting drug, substantially reduces excessive sleepiness in these individuals suffering from shift work disorder. The findings, published in early 2026, point to a practical tool for aligning alertness with demanding schedules.[1][2]
Shift Work Disorder Hits Hard
Early-morning shift workers, typically starting between 3 a.m. and 7 a.m., encounter a misalignment between their internal clocks and job demands. This condition, known as shift work disorder, manifests as chronic excessive sleepiness during work hours alongside insomnia during rest periods. Researchers noted that affected individuals often carry a double burden of fatigue on the job and insufficient recovery sleep.[2]
“They are often dealing with a double burden – excessive sleepiness during work hours and difficulty sleeping enough when they have the chance to rest,” stated Kirsi-Marja Zitting, lead investigator from Mass General Brigham. The disorder contributes to reduced productivity, mood disturbances, and elevated safety concerns in sectors like healthcare, manufacturing, and transportation. Long-term effects can extend to gastrointestinal problems, cardiovascular issues, and even heightened cancer risks in severe cases.
How Solriamfetol Targets Wakefulness
Solriamfetol, marketed as Sunosi, functions as a selective dopamine and norepinephrine reuptake inhibitor. The drug boosts levels of these neurotransmitters in the brain, which play crucial roles in promoting alertness and cognitive function. Unlike traditional stimulants, it offers a non-jittery path to sustained wakefulness, already approved for excessive sleepiness in narcolepsy and obstructive sleep apnea patients.[3]
Participants in the trial took the medication orally within 30 minutes of awakening, just before their shifts began. This timing aligned the drug’s effects with peak drowsiness periods, providing targeted relief without disrupting evening rest. The approach marked a tailored application for early-shift scenarios, distinct from broader wakefulness aids.
Clinical Trial Delivers Clear Results
The randomized, double-blind, placebo-controlled study enrolled nearly 100 adults diagnosed with shift work disorder and regular early-morning shifts. Over four weeks, participants underwent objective testing via the Maintenance of Wakefulness Test, where they resisted sleep in a dim, quiet room. Those receiving solriamfetol stayed awake 9.4 minutes longer on average compared to the placebo group, a statistically significant improvement.[4][5]
Subjective measures reinforced the gains. On the Epworth Sleepiness Scale, solriamfetol users reported markedly lower daytime drowsiness. Workers felt about four times less sleepy during shifts, based on self-assessments and functional evaluations. Simulated work tasks further confirmed enhanced performance and reduced lapses in attention.[6]
| Measure | Solriamfetol | Placebo |
|---|---|---|
| Maintenance of Wakefulness Test (mean increase) | +9.4 minutes | No significant change |
| Epworth Sleepiness Scale | Significant reduction | Limited improvement |
| Job Sleepiness Reports | 4x less likely | Higher incidence |
Business and Safety Implications Unfold
Employers stand to benefit from a more alert workforce, particularly in high-stakes environments where drowsiness leads to errors or accidents. The trial underscored solriamfetol’s potential to mitigate productivity losses tied to shift work, a issue affecting vast swaths of the labor market. Sectors reliant on round-the-clock operations could see gains in efficiency and employee well-being.[7]
Safety improvements loom large as well. Reduced sleepiness translates to fewer microsleeps and better decision-making during critical hours. While side effects appeared mild and comparable to placebo, ongoing monitoring will refine its profile for widespread use. The study’s first-of-its-kind focus on early shifts fills a prior research gap.[8]
- Targets dopamine and norepinephrine for natural alertness.
- Improves both objective and subjective sleepiness metrics.
- Supports productivity in 24/7 industries.
- Already FDA-approved for related conditions.
- Minimal disruption to off-shift sleep patterns.
Key Takeaways
- Solriamfetol extended wakefulness by over 9 minutes in tests.[4]
- Participants reported sharper focus and less fatigue at work.
- Offers a novel option for the millions grappling with dawn shifts.
This trial positions solriamfetol as a viable counter to the relentless fatigue of early shifts, potentially reshaping how businesses manage night owls turned morning warriors. As adoption grows, it could ease the human cost of non-stop operations. What do you think about this development for shift workers? Tell us in the comments.
